IC50 (binding)
|
nM
|
Compound was evaluated in vitro for the inhibitory concentration required to inhibit tissue plasminogen activator cleavage of the chromogenic substrate by 50%; Inactive
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
nM
|
In vitro inhibitory activity of the compound was evaluated against thrombolytic enzyme plasmin; Inactive
|
ChEMBL.
|
9934495
|
IC50 (binding)
|
nM
|
Compound was evaluated in vitro for the inhibitory concentration required to inhibit human serine protease enzyme plasmin by 50%; Inactive
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
0 nM
|
In vitro inhibitory activity of the compound was evaluated against thrombolytic enzyme plasmin; Inactive
|
ChEMBL.
|
9934495
|
IC50 (binding)
|
0 nM
|
Compound was evaluated in vitro for the inhibitory concentration required to inhibit human serine protease enzyme plasmin by 50%; Inactive
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
0 nM
|
Compound was evaluated in vitro for the inhibitory concentration required to inhibit tissue plasminogen activator cleavage of the chromogenic substrate by 50%; Inactive
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
= 6.2 nM
|
The compound was tested in vitro for inhibitory activity against Coagulation factor II
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
= 6.2 nM
|
In vitro inhibitory activity of the compound was evaluated against FIIa serine protease
|
ChEMBL.
|
9934495
|
IC50 (binding)
|
= 6.2 nM
|
In vitro inhibitory activity was evaluated against thrombin (FIIa)
|
ChEMBL.
|
9873569
|
IC50 (binding)
|
= 6.2 nM
|
Compound was evaluated in vitro for the inhibitory concentration required to inhibit human serine protease enzyme thrombin (FIIa) by 50%
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
= 6.2 nM
|
Inhibitory concentration of the compound required to inhibit human thrombin enzyme was determined
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
= 6.2 nM
|
The compound was tested in vitro for inhibitory activity against Coagulation factor II
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
= 6.2 nM
|
In vitro inhibitory activity was evaluated against thrombin (FIIa)
|
ChEMBL.
|
9873569
|
IC50 (binding)
|
= 6.2 nM
|
Compound was evaluated in vitro for the inhibitory concentration required to inhibit human serine protease enzyme thrombin (FIIa) by 50%
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
= 6.2 nM
|
Inhibitory concentration of the compound required to inhibit human thrombin enzyme was determined
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
= 791 nM
|
In vitro inhibitory activity was evaluated against human trypsin cleavage of the chromogenic substrate
|
ChEMBL.
|
9873569
|
IC50 (binding)
|
= 791 nM
|
Compound was evaluated in vitro for the inhibitory concentration required to inhibit human serine protease enzyme human trypsin by 50%
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
= 791 nM
|
Inhibitory concentration of the compound required to inhibit human trypsin enzyme was determined
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
= 791 nM
|
In vitro inhibitory activity was evaluated against human trypsin cleavage of the chromogenic substrate
|
ChEMBL.
|
9873569
|
IC50 (binding)
|
= 791 nM
|
Compound was evaluated in vitro for the inhibitory concentration required to inhibit human serine protease enzyme human trypsin by 50%
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
= 791 nM
|
Inhibitory concentration of the compound required to inhibit human trypsin enzyme was determined
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
= 1271 nM
|
The compound was tested in vitro for inhibitory activity against human trypsin
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
= 1271 nM
|
In vitro inhibitory activity of the compound was evaluated against human trypsin
|
ChEMBL.
|
9934495
|
IC50 (binding)
|
= 1271 nM
|
The compound was tested in vitro for inhibitory activity against human trypsin
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
= 1271 nM
|
In vitro inhibitory activity of the compound was evaluated against human trypsin
|
ChEMBL.
|
9934495
|
IC50 (binding)
|
> 2500 nM
|
The compound was tested in vitro for inhibitory activity against Coagulation factor X
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
> 2500 nM
|
In vitro inhibitory activity of the compound was evaluated against Coagulation factor X
|
ChEMBL.
|
9934495
|
IC50 (binding)
|
= 2500 nM
|
In vitro inhibitory activity was evaluated against thrombin factor Xa (FXa)
|
ChEMBL.
|
9873569
|
IC50 (binding)
|
> 2500 nM
|
In vitro inhibitory activity was evaluated against thrombolytic enzyme plasmin
|
ChEMBL.
|
9873569
|
IC50 (binding)
|
> 2500 nM
|
Compound was evaluated in vitro for the inhibitory concentration required to inhibit Coagulation factor X by 50%
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
= 2500 nM
|
Inhibitory concentration of the compound required to inhibit human factor Xa enzyme was determined
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
> 2500 nM
|
Inhibitory concentration of the compound required to inhibit human plasmin enzyme was determined
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
> 2500 nM
|
Inhibitory concentration of the compound required to inhibit human Tissue type plasminogen activator was determined
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
> 2500 nM
|
The compound was tested in vitro for inhibitory activity against Coagulation factor X
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
> 2500 nM
|
In vitro inhibitory activity of the compound was evaluated against Coagulation factor X
|
ChEMBL.
|
9934495
|
IC50 (binding)
|
= 2500 nM
|
In vitro inhibitory activity was evaluated against thrombin factor Xa (FXa)
|
ChEMBL.
|
9873569
|
IC50 (binding)
|
> 2500 nM
|
In vitro inhibitory activity was evaluated against thrombolytic enzyme plasmin
|
ChEMBL.
|
9873569
|
IC50 (binding)
|
> 2500 nM
|
Compound was evaluated in vitro for the inhibitory concentration required to inhibit Coagulation factor X by 50%
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
= 2500 nM
|
Inhibitory concentration of the compound required to inhibit human factor Xa enzyme was determined
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
> 2500 nM
|
Inhibitory concentration of the compound required to inhibit human plasmin enzyme was determined
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
> 2500 nM
|
Inhibitory concentration of the compound required to inhibit human Tissue type plasminogen activator was determined
|
ChEMBL.
|
No reference
|
Ki (binding)
|
= 1 nM
|
Evaluation of inhibition of transition state thrombin
|
ChEMBL.
|
10498222
|
Ki (binding)
|
= 1 nM
|
Evaluation of inhibition of transition state thrombin
|
ChEMBL.
|
10498222
|
Ratio (binding)
|
= 205
|
In vitro inhibitory activity of the compound was evaluated as ratio of trypsin by FIIa serine protease
|
ChEMBL.
|
9934495
|
Ratio (binding)
|
= 127.6
|
Ratio of thrombolytic enzyme plasmin to thrombin (FIIa) was evaluated
|
ChEMBL.
|
9873569
|
Ratio (binding)
|
= 205
|
Selectivity of the compound for Tryp over FIIa was determined
|
ChEMBL.
|
No reference
|
Ratio (binding)
|
= 205
|
In vitro inhibitory activity of the compound was evaluated as ratio of trypsin by FIIa serine protease
|
ChEMBL.
|
9934495
|
Ratio (binding)
|
> 403
|
Selectivity of the compound for FXa over FIIa was determined
|
ChEMBL.
|
No reference
|
Ratio (binding)
|
> 403
|
In vitro inhibitory activity of the compound was evaluated as ratio of FIIa serine protease by FXa serine protease
|
ChEMBL.
|
9934495
|
Ratio (binding)
|
= 403.2
|
Ratio of thrombin factor Xa (FXa) to thrombin (FIIa) was evaluated
|
ChEMBL.
|
9873569
|